Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021, or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-17272 BIO-TECHNE CORPORATION (Exact name of registrant as specified in its charter) Minnesota 41-1427402 (State or other jur ...

Washington, DC 20549 FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION For the quarterly period ended December 31, 2020, or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-17272 BIO-TECHNE CORPORATION (Exact name of registrant as specified in its charter) Minnesota 41-1427402 (State or other ju ...

Bio-Techne Corporation (NASDAQ:TECH) Q2 2021 Earnings Conference Call February 2, 2021 9:00 AM ET Company Participants David Clair - Senior Director, IR and Corporate Development Charles Kummeth - President and CEO Jim Hippel - CFO Conference Call Participants Puneet Souda - SVB Leerink Catherine Schulte - Robert W. Baird Alex Nowak - Craig-Hallum Capital Dan Arias - Stifel Jacob Johnson - Stephens Inc Patrick Donnelly - Citigroup Operator Good morning and welcome to the Bio-Techne Earnings Conference Call ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020, or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-17272 Non-accelerated filer ☐ Smaller reporting company ☐ BIO-TECHNE CORPORATION (Exact name of registrant as specified ...

Bio-Techne Corporation (NASDAQ:TECH) Q1 2021 Results Earnings Conference Call November 5, 2020 2:00 AM ET Company Participants David Clair - Senior Director, Investor Relations and Corporate Development Chuck Kummeth - Chief Executive Officer Jim Hippel - Chief Financial Officer Conference Call Participants Puneet Souda - SVB Leerink Dan Arias - Stifel Patrick Donnelly - Citigroup Alex Nowak - Craig-Hallum Capital Dan Leonard - Wells Fargo Operator Good morning, and welcome to the Bio-Techne Earnings Confer ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2020, or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-17272 BIO-TECHNE CORPORATION (Exact name of registrant as specified in its charter) Washington, DC 20549 FORM 10-K Minnesota 41-1427402 (State or other jurisdiction ...

Bio-Techne Corporation (NASDAQ:TECH) Q4 2020 Earnings Conference Call August 4, 2020 9:00 AM ET Company Participants David Clair – Senior Director, Investor Relations and Corporate Development Chuck Kummeth – Chief Executive Officer Jim Hippel – Chief Financial Officer Conference Call Participants Puneet Souda – SVB Leerink Catherine Schulte – Baird Dan Arias – Stifel Patrick Donnelly – Citi Jacob Johnson – Stephens Alex Nowak – Craig-Hallum Capital Group Operator Good morning, and welcome to the Bio-Techne ...

| --- | --- | --- | --- | --- | --- | --- | --- | |-------|---------------------------------------|-------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | WHERE SCIENCE INTERSECTS INNOVATION | | | | | | | | | Corporate Presentation May 2020 | | | | | | | | | | | | | | | | | | | | | | | | | © 2020 Bio-Techne®. All rights reserved. | --- | --- ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020, or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-17272 BIO-TECHNE CORPORATION (Exact name of registrant as specified in its charter) Minnesota 41-1427402 (State or other jur ...

Bio-Techne Corporation (NASDAQ:TECH) Q3 2020 Earnings Conference Call April 30, 2020 9:00 AM ET Company Participants David Clair – Senior Director, Investor Relations and Corporate Development Chuck Kummeth – Chief Executive Officer Jim Hippel – Chief Financial Officer Conference Call Participants Puneet Souda – Leerink Partners Catherine Schulte – Baird Dan Arias – Stifel Dan Leonard – Wells Fargo Jacob Johnson – Stephens Patrick Donnelly – Citi Paul Knight – Janney Montgomery Scott Alex Nowak – Craig-Hall ...